Physician profile
Todd E Kennedy
NPI 1720080393
$3,321.65
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,911 · 2022: $1,326 · 2023: $64.40 · 2024: $20.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $84.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $84.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $705.62 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $441.78 | 2021-2022 | |
| Medtronic, INC. | $299.35 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.24 | 2021-2022 | |
| Lilly USA, LLC | $190.45 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $186.62 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $172.12 | 2021-2023 | Recorlev |
| Corcept Therapeutics | $169.86 | 2021-2022 | |
| Dexcom, INC. | $134.24 | 2021-2022 | |
| Amgen INC. | $118.26 | 2021-2022 | |
| Lifescan, INC. | $96.58 | 2021-2022 | |
| Abbott Laboratories | $96.32 | 2021 | |
| Ibsa Pharma INC. | $66.26 | 2021 | |
| Tandem Diabetes Care, INC. | $56.42 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.22 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $38.73 | 2021 | |
| Grt US Holding, INC. | $38.33 | 2022 | |
| Amarin Pharma, INC. | $37.83 | 2021-2022 | |
| Abbvie INC. | $32.97 | 2022 | |
| Pfizer INC. | $32.19 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $29.76 | 2021 | |
| Recordati_rare_diseases_inc. | $21.43 | 2021 | |
| Electronic Waveform Lab, INC. | $20.24 | 2024 | |
| Horizon Therapeutics Plc | $19.47 | 2021 | |
| Amryt Pharma Holdings LTD | $19.03 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.76 | 2021 | |
| Insulet Corporation | $17.37 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.